Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

Friday, May 23, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BETHESDA, Md., May 22 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietaryantibodies for the treatment of cancer, inflammation and autoimmune diseases,today announced that the company will provide an update on the phase 1clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10thInternational Conference on Malignant Lymphomas, taking place June 4-7 inLugano, Switzerland.

The presentation, entitled, "Anti-CD19 BiTE Antibody MT103 (MEDI-538)Induces Durable Objective Responses in Patients with Relapsed Non-Hodgkin'sLymphoma (NHL). Update from Ongoing Phase I Study MT103-104" will take placeduring Poster Session I from 8:00am to 6:00pm on June 5th, 2008 in the MarqueeParco Ciani. Meeting abstracts will first be available during the week of theconference.

The 10th International Conference on Malignant Lymphoma gathers 3,000leading physicians from all over the world: hematologists, clinicaloncologists, pathologists and leading researchers involved in the study andtreatment of lymphoid neoplasms, including multiple myeloma and CLL.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, orcell-destroying, T cells against tumor cells, and represent a new therapeuticapproach to cancer therapy. BiTE antibodies have been shown to induce animmunological synapse between a T cell and a tumor cell in the same manner asobserved during physiological T cell attacks. These cytolytic synapses enablethe delivery of cytotoxic proteins from T cells into tumor cells, ultimatelyinducing a self-destruction process in the tumor cell referred to asapoptosis, or programmed cell death. In the presence of BiTE antibodies, Tcells have been demonstrated to serially eliminate tumor cells, which explainsthe activity of BiTE antibodies at very low concentrations and at very lowratios of T cells to target cells. Through the process of killing cancercells, T cells proliferate, which leads to an increased number of T cells atthe site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies andhave been generated based on Micromet's proprietary BiTE antibody platform.The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and hasprovided proof-of-concept in an ongoing phase 1 clinical study in patientswith advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326)and is the first BiTE antibody with potential applications in the treatment ofsolid tumors, is in a phase 1 clinical trial in patients with lung and gastriccancers. Two additional BiTE antibodies, targeting CD33 and MCSP, are inpreclinical development.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel,proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. Four of its antibodies are currently in clinical trials,while the remainder of the product pipeline is in preclinical development. TheBiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment ofpatients with acute lymphoblastic leukemia and in a phase 1 clinical trial forthe treatment of patients with non-Hodgkin's lymphoma. BiTE antibodiesrepresent a new class of antibodies that activate a patient's own cytotoxic Tcells, considered the most powerful "killer cells" of the human immune system,to eliminate cancer cells. Micromet is developing MT103 in collaboration withMedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTEantibody in clinical trials, and is being developed by Micromet in a phase 1clinical trial for the treatment of patients with lung and gastric cancer.The third clinical stage antibody is adecatumumab, also known as MT201, ahuman monoclonal antibody which targets epithelial cell adhesion molecule(EpCAM)-expressing solid tumors. Micromet is developing adecatumumab incol

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store